Rules-Based Medicine Newswire

Rules-Based Medicine Newswire

Comprehensive Real-Time News Feed for Rules-Based Medicine.

Results 1 - 20 of 312 in Rules-Based Medicine

  1. Heinrich Dreismann Sells 6,000 Shares of Myriad Genetics, Inc. (MYGN) StockRead the original story w/Photo

    Tuesday | AmericanBankingNews.com

    Myriad Genetics, Inc. Director Heinrich Dreismann sold 6,000 shares of the company's stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $33.50, for a total transaction of $201,000.00.

    Comment?

  2. Myriad's BRACAnalysis CDx Test Effectively Identified Metastatic ...Read the original story

    Tuesday | PressReleasePoint

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial showed Myriad's BRACAnalysis CDxA test successfully identified patients with metastatic breast cancer who responded to Pfizer's investigational PARP inhibitor, talazoparib. The EMBRACA trial data were presented last week at the 2017 San Antonio Breast Cancer Symposium .

    Comment?

  3. Vident Investment Advisory LLC Has $3.91 Million Holdings in Myriad Genetics, Inc.Read the original story w/Photo

    Saturday Dec 9 | Daily Political

    Vident Investment Advisory LLC decreased its holdings in shares of Myriad Genetics, Inc. by 30.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 108,092 shares of the company's stock after selling 46,975 shares during the period.

    Comment?

  4. Myriad Genetics Presents Results From Two Important EndoPredict...Read the original story

    Friday Dec 8 | PressReleasePoint

    SALT LAKE CITY, Dec. 08, 2017 -- Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict A are being featured at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas. EndoPredict is a second-generation prognostic gene expression test for patients with breast cancer.

    Comment?

  5. Caisse DE Depot ET Placement DU Quebec Invests $9.08 Million in Myriad Genetics, Inc. (MYGN) StockRead the original story w/Photo

    Friday Dec 8 | IntersportsWire

    Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Myriad Genetics, Inc. during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 250,000 shares of the company's stock, valued at approximately $9,083,000.

    Comment?

  6. Myriad Genetics Presents Pivotal Validation Study for New riskScorea ...Read the original story

    Wednesday Dec 6 | Customer Interaction Solutions

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to better define the risk of breast cancer in women of European ancestry who test negative for a hereditary cancer mutation with the myRiskA Hereditary Cancer test. The results are being featured in a Spotlight presentation today at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas.

    Comment?

  7. Myriad Genetics Presents Pivotal Validation Study for New riskScore...Read the original story w/Photo

    Wednesday Dec 6 | GlobeNewswire

    The results are being featured in a Spotlight presentation today at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas. "Myriad Genetics is the first to bring to market a comprehensive approach to lifetime breast cancer risk assessment that includes 28 genes, family history evaluation, and well-validated SNPs through riskScore," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics.

    Comment?

  8. Virginia Retirement Systems Et Al Cuts Stake in Myriad Genetics, Inc.Read the original story w/Photo

    Wednesday Dec 6 | IntersportsWire

    Virginia Retirement Systems ET AL cut its position in Myriad Genetics, Inc. by 20.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 48,500 shares of the company's stock after selling 12,300 shares during the period.

    Comment?

  9. Leadership In Hereditary Cancer Testing Will Drive Myriad Genetics' Stock In 2018Read the original story w/Photo

    Tuesday Dec 5 | Seeking Alpha

    Myriad Genetics has been rapidly spreading its presence in the molecular diagnostics market. With 12 proprietary molecular diagnostics products, the company is making rapid advances in studying genes and assessing patients' risk for developing certain cancers as well as specific neurological and autoimmune conditions.

    Comment?

  10. Myriad Genetics, Inc. (MYGN) Expected to Post Quarterly Sales of $188.75 MillionRead the original story w/Photo

    Tuesday Dec 5 | AmericanBankingNews.com

    Wall Street brokerages forecast that Myriad Genetics, Inc. will report $188.75 million in sales for the current fiscal quarter, according to Zacks . Six analysts have made estimates for Myriad Genetics' earnings.

    Comment?

  11. ValuEngine Lowers Myriad Genetics (MYGN) to HoldRead the original story w/Photo

    Monday Dec 4 | IntersportsWire

    Several other brokerages have also issued reports on MYGN. Morgan Stanley reissued an underweight rating and issued a $24.00 price target on shares of Myriad Genetics in a report on Friday, October 6th.

    Comment?

  12. OxFORD Asset Management LLP Purchases 18,988 Shares of Myriad Genetics, Inc.Read the original story w/Photo

    Monday Dec 4 | IntersportsWire

    OxFORD Asset Management LLP raised its position in Myriad Genetics, Inc. by 9.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission . The firm owned 220,980 shares of the company's stock after purchasing an additional 18,988 shares during the quarter.

    Comment?

  13. Zacks: Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Post Earnings of $0.24 Per ShareRead the original story w/Photo

    Sunday Dec 3 | AmericanBankingNews.com

    Equities analysts expect Myriad Genetics, Inc. to post earnings per share of $0.24 for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Myriad Genetics' earnings.

    Comment?

  14. Myriad Genetics (MYGN) Stock Rating Lowered by ValuEngineRead the original story w/Photo

    Saturday Dec 2 | AmericanBankingNews.com

    Several other analysts have also issued reports on MYGN. BidaskClub lowered shares of Myriad Genetics from a "buy" rating to a "hold" rating in a report on Thursday, August 3rd.

    Comment?

  15. Myriad Genetics (MYGN) Rating Lowered to Hold at ValuEngineRead the original story w/Photo

    Saturday Dec 2 | The Breeze

    Several other research analysts also recently weighed in on MYGN. BidaskClub downgraded shares of Myriad Genetics from a "buy" rating to a "hold" rating in a report on Thursday, August 3rd.

    Comment?

  16. Royal Bank of Canada Has $125,000 Stake in Myriad Genetics, Inc.Read the original story w/Photo

    Tuesday Nov 28 | IntersportsWire

    Royal Bank of Canada reduced its position in Myriad Genetics, Inc. by 60.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,860 shares of the company's stock after selling 7,362 shares during the quarter.

    Comment?

  17. 5,632 Shares in Myriad Genetics, Inc. (MYGN) Purchased by Teacher Retirement System of TexasRead the original story w/Photo

    Sunday Nov 26 | Daily Political

    Teacher Retirement System of Texas bought a new stake in Myriad Genetics, Inc. during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission . The institutional investor bought 5,632 shares of the company's stock, valued at approximately $204,000.

    Comment?

  18. Myriad Genetics, Inc. (MYGN) Receives Consensus Recommendation of "Hold" from AnalystsRead the original story w/Photo

    Thursday Nov 23 | AmericanBankingNews.com

    Shares of Myriad Genetics, Inc. have been given an average rating of "Hold" by the fourteen ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, seven have given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company.

    Comment?

  19. Brokerages Expect Myriad Genetics, Inc. (MYGN) Will Announce Quarterly Sales of $188.75 MillionRead the original story w/Photo

    Friday Nov 17 | AmericanBankingNews.com

    Brokerages forecast that Myriad Genetics, Inc. will post sales of $188.75 million for the current quarter, Zacks reports. Six analysts have provided estimates for Myriad Genetics' earnings.

    Comment?

  20. Myriad Genetics, Inc. (MYGN) Stock Price Up 6.9%Read the original story w/Photo

    Thursday Nov 16 | The Breeze

    Myriad Genetics, Inc. shares rose 6.9% during mid-day trading on Thursday . The company traded as high as $33.80 and last traded at $33.41.

    Comment?